EU/3/10/782: Orphan designation for the treatment of cystic fibrosis
Table of contents
On 20 September 2010, orphan designation (EU/3/10/782) was granted by the European Commission to Mucokinetica Ltd, United Kingdom, for nafamostat mesilate for the treatment of cystic fibrosis.
Treatment of cystic fibrosis
|Orphan designation status||
|EU designation number||
|Date of designation||
53 Cavendish Road
London SW12 0BL
Telephone: +44 7774 12 1180
Telefax: +44 20 8673 2266
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: